Drug Profile
PX 1031
Alternative Names: PX 103.1Latest Information Update: 25 Jun 2009
Price :
$50
*
At a glance
- Originator Pharmexa
- Class Cancer vaccines
- Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 22 Jun 2009 Affitech AS has merged with Pharmexa to form Affitech A/S
- 20 Dec 2006 Pharmexa and Ichor Medical Systems have entered into a collaborative agreement for PX 1031
- 28 May 2003 Suspended - Phase-I/II for Breast cancer in Denmark (unspecified route)